More information

The constant renewal of bone tissues relies on the balanced interplay of bone forming osteoblasts and bone resorbing osteoclasts. Disturbances within this balanced system can lead to severe diseases like osteoporosis, bone metastases and osteogenesis imperfecta. The major research interest of the bone lab is therefore to analyze the molecular mechanisms of the communication between osteoblasts and osteoclasts. Thereby, we focus on four different major research areas:

(I) Osteoimmunology

In the Osteoimmunology research area, we investigate the interactions between the immune system and bone cells in glucocorticoid- and arthritis-induced bone loss models. A major focus is thereby to define the role of the RANKL/OPG system and the Wnt pathways in health and disease. We found that Wnt5a represents a key osteoimmunological cytokine that confers signals from MSC to HSC.

(II) Osteooncology

We found that prostate cancer cells utilize the very same signals used by osteoblasts to communicate to other cells. In the Osteooncology field, we therefore aim to elucidate the underlying mechanisms of bone metastasis forming as a frequent complication within breast and prostate cancer. With that, we intend to identify and validate new targets to improve cancer treatment. All activities in this research take place within the DFG research consortium SKELMET.

(III) Bone Health in Diabetes

Diabetes mellitus is associated with an increased risk of osteoporosis and fragility fractures. We found that bone regeneration in diabetes is delayed due to suppressed osteoblast function and can be accelerated by sclerostin inhibition. In this research area, we study the mechanisms of bone remodelling and bone repair in a preclinical rat model of type 2 diabetes mellitus to potentially derive insights on how to improve health and life quality of patients with diabetes.

(IV) Matrix Biology and Bone Remodelling

Glycosaminoglycans (GAG) such as hyaluronan and chondroitin sulfate are the major organic extracellular matrix components in bone. We found that oversulfation of these GAGs is critically involved in suppressing osteoclast function. In this research area, we investigate how GAGs modulate osteoclast functions and bone remodelling to eventually derive knowledge on how to improve the development of new adaptive biomaterials

Lorenz Hofbauer Research: Figure
Fig.: Effects of Sclerostin antibody treatment in diabetic conditions. (A) and (B) Treatment of diabetic ZDF rats without sclerostin antibody results in less bone formation, shown in black (A) and fluorescent green (B), respectively. (C) and (D) Treatment of diabetic ZDF rats with sclerostin antibody over a period of 12 weeks leads to an increase in bone mass and bone strength. Similar results were also found in non-diabetic rats (not shown here).

Future Projects and Goals

In future, we will continue our research activities in the above mentioned four research areas, thereby further strengthening our current scientific and translational experience in bone biology. In addition, we want to put special emphasis to a new interface research field: OsteoHematology. There, we together with colleagues of the hematology department aim at assessing the impact of iron homeostasis on the mutual interactions of skeletal and hematopoietic cells and at elucidating the role of the Wnt signaling pathway in this interdisciplinary research field.

Methodological and Technical Expertise

  • Comprehensive characterization of bone physiology using µCT
  • finite element analysis
  • dynamic histomorphometry


since 2007
Professor of Medicine and Head of the Division of Endocrinology, Diabetes, Bone Diseases, Dresden Technical University Medical Center

Heisenberg Senior Research Programme, Philipps-University, Marburg

Residency at Department of Medicine, Philipps-University, Marburg

DFG-Research Fellowship; Mayo Clinic, Rochester, USA

DFG-Research Fellowship; Mayo Clinic, Rochester, USA

Studies of Medicine at LMU Munich and Mayo Clinic Rochester, New York University, Harvard University, Yale University, USA

MD at University of Munich

More Information

Selected Publications

Rauner M, Stein N, Winzer M, Goettsch C, Zwerina J, Schett G, Distler JH, Albers J, Schulze J, Schinke T, Bornhäuser M, Platzbecker U, Hofbauer LC.
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production.
J Bone Miner Res. 2012;27:575-85.

Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, Rauner M.
Selective glucocorticoid receptor modulation maintains bone mineral density in mice.
J Bone Miner Res. 2012;27:2242-50.

Rachner TD, Hadji P, Hofbauer LC.
Novel therapies in benign and malignant bone diseases.
Pharmacol Ther. 2012;134:338-44.

Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC.
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.
J Bone Miner Res. 2012 Oct 29. doi:10.1002/jbmr.1803.

Salbach J, Kliemt S, Rauner M, Rachner TD, Goettsch C, Kalkhof S, von Bergen M, Möller S, Schnabelrauch M, Hintze V, Scharnweber D, Hofbauer LC.
The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways.
Biomaterials. 2012;33:8418-29


Division of Endocrinology,
Diabetes, and Bone Diseases
Department of Medicine III
Dresden University Medical Center
Fetscherstraße 74
01307 Dresden